澳门赌场招聘-赌场有哪些_免费百家乐追号软件_全讯网最新资讯网址 (中国)·官方网站

Medical Research

Repair Defected Nerves and Benefit Thousands of Families

Share
  • Updated: Sep 10, 2012
  • Written:
  • Edited:
Source: News Center
Written by: News Center and Guangzhou Zhongda Holdings Co., Ltd
Photo by: Kai Saer

On the morning of September 6, “the press conference of the successful development of world advanced level artificial nerve conduit for the repair of peripheral nerve defect--- 'Shen Qiao’in Sun Yat-sen University” was held in SYSU. The press conference was co-hosted by Guangzhou Zhongda Holdings Co., Ltd and the Publicity Department of SYSU Party Committee, co-organized by Guangzhou Zhongda Medical Equipment Co., Ltd and The First Affiliated Hospital of Sun Yat-sen University. Academician Zhong Shizhen, member of Guangdong Provincial Scientific and Technological Achievements Appraisal Meeting and professor of Southern Medical University, Prof. Zhu Jiakai, Prof. Liu Xiaolin and Director Gu Liqiang, members of “Shen Qiao” scientific research team, The First Affiliated Hospital of Sun Yat-sen University, Gu Xiaofeng, General Manager of Guangzhou Zhongda Holdings Co., Ltd, Yang Yuexiong, General Manager of Guangzhou Zhongda Medical Equipment Co., Ltd, and journalists from many media organizations attended the conference. The press conference was chaired by Xie Manhua, Director of the Publicity Department of SYSU Party Committee.

"Acellular nerve allograft artificial nerve conduit for the repair of nerve defect" --- "Shen Qiao” (meaning “Magic Bridge”) is used for bridging nerve defects as an alternative to nerve autografts in peripheral nerve repair. “Shen Qiao” has been approved by State Food and Drug Administration (SFDA), granted production registration certificate and approved for clinical use and sale on the market. Independently developed in China with completely independent intellectual property right, “Shen Qiao" is the only officially approved artificial nerve conduit for the repair of nerve defect in the country since worldwide similar product made in the US was first approved for clinical use and sale on the market in 2008. In the scientific appraisal co-organized by Guangdong Provincial Department of Science and Technology and Department of Health of Guangdong Province, and made by top experts in the same field in China, the “Shen Qiao” series of research achievements is said to be “on the whole at the advanced level in the world and some of its technologies have reached the world’s leading level”.


A scene of the press conference

At the press conference, Prof. Liu Xiaolin described the development background, research process and research achievements of “Shen Qiao” and briefly introduced the future upgrades of the product. Prof Zhu Jiakai compared “Shen Qiao” with a similar product manufactured by an American company in specifications, storage and clinical test process, demonstrating that “Shen Qiao” is superior to the similar product in these aspects and achieves the world’s top level. General Manager Yang Yuexiong introduced the benefits brought by the combination of production, study and research.

Academician Zhong Shizhen, clinical anatomy authority and leader of the expert group of the achievement appraisal meeting, affirmed the result of “Shen Qiao” in the appraisal meeting: “it is on the whole at internationally advanced level, and in part reaches international leading level”, and said that it is also a major breakthrough in translational medicine in China. He pointed out that “Shen Qiao” meets the requirement of “2011” Collaborative Innovation Program proposed by General Secretary Hu Jintao, and it will promote the organic integration of social benefits and economic benefits. The launch of “Shen Qiao” is a great inspiration to academic researchers and good news for people with nerve injury.
 

A sample of “Shen Qiao"

It is learned that “Shen Qiao” is mainly developed by Guangzhou Zhongda Medical Equipment Co., Ltd and the scientific research team led by Prof. Liu Xiaolin of The First Affiliated Hospital of Sun Yat-sen University. The team also includes researchers from School of Chemistry and Chemical Engineering at Sun Yat-sen University. Since Guangzhou Zhongda Medical Equipment Co., Ltd is affiliated to Guangzhou Zhongda Holdings Co., Ltd, therefore, Sun Yat-sen University has completely independent intellectual property right. It is a beneficial attempt and an excellent achievement of collaborative innovation in the university.

Up to now, the repair of peripheral nerve injuries caused by all kinds of accidents, natural disasters and even wars is still a worldwide challenge, especially the repair of nerve defects caused by injuries. In the recent two centuries, medical scientists and material scientists have attempted various methods and selected various materials to repair nerve defects, but the ideal results have not been achieved. The “rob one’s belly to cover one’s back” style of using nerve autografts in the repair is a common clinical approach and a helpless choice because even if autologous nerve grafting is performed for reconstruction, in addition to donor site morbidities that are hard to accept, the therapeutic outcome is still not ideal. Worldwide the first acellular nerve allograft artificial nerve conduit for the repair of nerve defect is Avance? Nerve Graft manufactured by AxoGen Inc. in the US, which was officially introduced to the market in 2008. The research team in Sun Yat-sen University started to develop the product at the same time with their fellow scientists in the US at the beginning of the century. In 2008, the research team led by Prof. Liu Xiaolin developed a similar product --- "Shen Qiao", however, Sun Yat-sen University follows the strict requirements of SFDA and makes an official announcement after nearly 3 years of clinical research observations. “Shen Qiao" shows that China ranks among the first in the world in tissue engineered nerve grafts and product development and it fills a domestic blank.

"Shen Qiao" is an acellular nerve graft obtained through extracted treatment of native peripheral nerves, it is mainly composed of extracellular matrix, and it does not contain any cells but preserves the intact structure similar to native nerves. When it is bridged at the nerve stumps, its unique three-dimensional structure and rich extracellular matrix provide good physical and biological environment for the growth of the regenerated nerve. It can lead and support the regenerated nerve to grow from the proximal to the distal stumps of nerve, enable the regenerated nerve to reach the distal end through the defected area, and finally restore innervation of the target organ. “Shen Qiao” can meet the physical, chemical and biological needs of artificial nerve conduit for the repair of nerve defect, avoid a variety of complications caused by autologous nerve grafting to repair defected nerves, and it is the most ideal product at the present. In our country, every year about 400,000 to 600,000 people have nerve defects due to injuries in industrial accidents, natural disasters and individual accidents, and at least 450,000 centimeters of artificial nerve conduit for the repair of nerve defect are needed. The launch of “Shen Qiao” on the market will directly benefit tens of thousands of patients who are disabled due to nerve defects, and help them to regain ability to live and work, and reduce the economic and ethical burdens of their families and the society. In particular, it has great strategic significance in natural disasters and war.
TOP
打牌网| 吴忠市| 百家乐官网缩水软件| 可以玩百家乐官网的博彩公司| 百家乐官网视频裸聊| 百家乐官网单跳投注法| TT娱乐城投注,| 绥宁县| A8百家乐官网现金网| 顶尖百家乐官网学习| 玩百家乐官网有何技巧| 狮威百家乐官网的玩法技巧和规则| 自己做生意怎样才能带来财运| 房产| 任我赢百家乐官网自动投注分析系统| 真人百家乐官网开户优惠| 悦榕庄百家乐官网的玩法技巧和规则| 澳门百家乐海星王| 在线百家乐3d| 威尼斯人娱乐场门票| 大发888娱乐城在线存款| 大发888怎么玩| 任你博| 百家乐官网出千赌具| 百家乐官网任你博娱乐网| 百家乐官网b28博你发v| 百家乐棋牌游戏正式版| 威尼斯人娱乐城代理| 百家乐ag厅投注限额| 皇冠百家乐代理网| 澳门百家乐娱乐网| 大发888体育官网| 威海市| 百家乐官网博乐36bol在线| 百家乐关键词| 威尼斯人娱乐城老品牌值得信赖| 博彩网站评级| 广州百家乐官网牌具公司| 百家乐官网谋略| 模拟百家乐下载| 棋牌游戏大厅|